J

Johnson & Johnson

Makes prescription drugs and medical devices

Territory Account Manager - Trauma

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Jaipur, Rajasthan, India
In PersonField-based role in Jaipur, covering all of Rajasthan.
Sales & Account ManagementField Sales

About the job

Requirements
  • A science graduate qualification is preferred.
  • A minimum of 4–5 years of experience in medical device sales is required.
  • Experience managing healthcare professional key opinion leaders is required.
  • Proficiency in Hindi or the language of the state and English is required.
Responsibilities
  • Sell franchise products and implants within the assigned territory.
  • Sell equipment and machines, and close their Comprehensive Annual Maintenance Contracts.
  • Work with hospital biomedical teams and purchasing departments to generate demand, negotiate, and close Power Systems deals.
  • Provide the manager with weekly and monthly sales action plans reflecting the account activities required to achieve sales objectives.
  • Analyze sales reports to identify opportunities and routine problems, analyze causes, and recommend solutions.
  • Negotiate and close sales in routine situations and, with guidance, handle more complex deals.
  • Participate in trade displays and conferences when required.
  • Develop an understanding of customer needs to identify sales opportunities.
  • Respond to surgeons’ daily implant requirements, understand fracture-specific implant needs, and recommend solutions as a product consultant.
  • Identify tender and contract opportunities and work with colleagues to deliver them.
  • Develop an effective and efficient territory plan with guidance.
  • Identify and train surgeons on new technologies and solutions through consultations in surgery, one-on-one sales calls, and group training sessions.
  • Demonstrate products in one-to-one calls and guide surgeons through product technical guides.
  • Work with the manager to identify customer in-service needs that support efficient and effective product use.
  • Develop and maintain relationships with customers at all levels, including CSSD teams, operating theatre in-charges, and biomedical personnel.
  • Coordinate and deliver in-service education sessions with assistance.
  • Prepare a plan, with guidance, to optimize key account development and sales growth.
  • Identify and document key customers and decision-makers.
  • Understand key account growth strategies.
  • Identify and optimize cross-selling opportunities and work with managers and colleagues to realize them.
  • Manage key-account consigned inventory and maintain consigned instruments.
  • Provide customer support on inventory within company guidelines.
  • Develop and continually improve knowledge of product features, benefits, correct application and usage, anatomy, physiology, and medical procedures through practical experience, training, and learning from key end-users.
  • Demonstrate product application and usage, and differentiate products from competitors’ products.
  • Develop understanding of competitors’ products and their features, advantages, and benefits.
  • Gather information on current practices, behaviors, and attitudes.
  • Obtain usage data for trained surgeons and monitor adoption.
  • Develop and implement the distribution network for the assigned territory.
  • Maintain distributor stock counts and replenish stock regularly to ensure complete stock availability for surgeries.
  • Maintain instrument effectiveness and initiate replacement of damaged instruments regularly.
  • Ensure distributor health meets agreed guidelines.
  • Manage accounts receivable, operating expenses, transportation, advertising and promotion, entertainment, and travel judiciously while ensuring sustainable productivity.
  • Obtain prior approval for budget variations.
  • Follow sample issuance and coordination guidelines.
  • Agree expense budgets and guidelines with the immediate manager.
  • Plan sample and expense use to optimize utilization within budget.
  • Identify specific actions to improve job performance.
  • Participate in nominated training programs.
  • Use active self-learning strategies to maintain knowledge.
  • Work to achieve high performance in knowledge tests and competency assessments related to training.
  • Apply new learning effectively on the job.
  • Maintain a responsible and ethical approach while pursuing business outcomes.
  • Conduct business in accordance with the ethics and values expressed in the Credo.
  • Maintain customer relationships based on high ethical standards.
Desired Qualifications
  • Experience in trauma is preferred.
  • Accountability.
  • Channel management.
  • Cross-selling.
  • Customer acquisition strategy.
  • Customer centricity.
  • Customer effort score.
  • Goal attainment.
  • Hospital operations.
  • Innovation.
  • Market opportunity assessment.
  • Medicines and device development and regulation.
  • Process orientation.
  • Relationship building.
  • Sales.
  • Solutions selling.
  • Sustainable procurement.
  • Vendor selection.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.